BioAtla (NASDAQ: BCAB)
$0.38
(1.4%)
$0.01
Price as of August 7, 2025, 4:00 p.m. ET
BioAtla Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioAtla Company Info
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.